Adult T-cell Leukemia/Lymphoma (ATLL)
Trusted educational information about HTLV-1, transmission, associated diseases, and research.
What is ATLL?
Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive cancer of T-lymphocytes caused by HTLV-1 infection.
It usually develops decades after initial infection and occurs in a small percentage of individuals carrying HTLV-1.
ATLL diagnosis typically rests on the combination of compatible morphology, mature T-cell phenotype, demonstration or strong evidence of clonal disease, and HTLV-1 positivity.
Types of ATLL
ATLL is generally classified into four clinical subtypes.
Acute ATLL
- Aggressive disease
- High white blood cell counts
- Organ involvement
- Rapid progression
Lymphoma-type ATLL
- Enlarged lymph nodes
- Less circulating disease
- Often aggressive
Chronic ATLL
- Slower progression
- May initially behave less aggressively
Smoldering ATLL
- Indolent form
- Often involves skin or blood
- Requires close monitoring
- Rapid progression
Symptoms of ATLL
Symptoms vary depending on subtype but may include:
- Enlarged lymph nodes
- Fatigue
- Fevers
- Night sweats
- Weight loss
- Skin lesions or rashes
- Skin lesions or rashes
- Elevated calcium levels
- Elevated calcium levels
- Frequent infections
- Enlarged liver or spleen
How is ATLL diagnosed?
Diagnosis may involve:
01
Blood tests
02
Lymph node or skin biopsy
03
Flow cytometry
04
Bone marrow biopsy
05
HTLV-1 testing
06
PET/CT imaging
07
Molecular and genetic testing
Specialized hematopathology review is often important.
Treatment Options
There is currently no definitive cure for ATLL, but treatment may help reduce inflammation and slow progression.
- Combination chemotherapy
- Antiviral/immunomodulatory therapy
- Monoclonal antibodies (such as mogamulizumab)
- Stem cell transplantation
- Cellular therapies including CAR T-cell therapy (investigational)
- Clinical trials
Some patients with aggressive disease may require urgent treatment.
Stem cell transplantation
Allogeneic stem cell transplantation may offer the best chance for long-term remission and cure in patients with aggressive ATLL.
This approach replaces diseased immune cells with healthy donor cells and may produce a graft-versus-ATLL effect.
Research and future therapies
Active research areas include:
- CRISPR-engineered CAR T-cell therapies
- Targeted therapies
- Immune checkpoint modulation
- Viral-targeted therapies
- Vaccine strategies
- Precision medicine approaches
Research and future therapies
Active research areas include:
- CRISPR-engineered CAR T-cell therapies
- Targeted therapies
- Immune checkpoint modulation
- Viral-targeted therapies
- Vaccine strategies
- Precision medicine approaches